Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Parkinson's infusion tested in everyday clinics

NCT ID NCT07382440

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study follows 120 adults with advanced Parkinson's disease in Belgium who are prescribed a drug called Foslevodopa/Foscarbidopa. The drug is given as a continuous infusion under the skin to help control symptoms. Researchers will track how much 'off' time (when symptoms like tremors and stiffness return) patients experience over 18 months in routine care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Foslevodopa/Foscarbidopa
What this could lead to
If successful, this study could confirm that this drug infusion effectively reduces 'off' time (when symptoms return) for advanced Parkinson's patients in everyday care.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only includes 120 people in Belgium, so findings may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with advanced Parkinson's Disease receiving Foslevodopa/Foscarbidopa treatment in accordance with the local label requirements in Belgium.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant diagnosed with Advanced Parkinson's Disease (PD), aged 18 years or older able to provide voluntary informed consent. * Participant evaluated for commercially available continuous subcutaneous Foslevodopa/Foscarbidopa (LDp/CDp) in the hospital at the clinician's discretion as part of his/her routine clinical care and the intention to administer subcutaneous LDp/CDp made prior to and independent of recruitment into the study. Exclusion Criteria: * Participant participating in an interventional research study (not including noninterventional studies) during the administration of LDp/CDp. * Participant evaluated for commercially available continuous subcutaneous LD/CDp outside of the hospital.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    12 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AZ Oostende /ID# 279461

    RECRUITING

    Ostend, West-Vlaanderen, 8400, Belgium

  • AZ Sint-Lucas /ID# 279453

    RECRUITING

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • AZ-Delta. /ID# 279437

    RECRUITING

    Roeselare, West-Vlaanderen, 8800, Belgium

  • Algemeen Ziekenhuis Sint-Jan Brugge /ID# 279422

    RECRUITING

    Bruges, West-Vlaanderen, 8000, Belgium

  • Az Groeninge Campus Kennedylaan /ID# 279423

    RECRUITING

    Kortrijk, West-Vlaanderen, 8500, Belgium

  • Centre Hospitalier De Wallonie Picarde - Site Notre Dame /ID# 279452

    RECRUITING

    Tournai, Hainaut, 7500, Belgium

  • Chu Tivoli /ID# 279455

    RECRUITING

    La Louvière, Hainaut, 7100, Belgium

  • Imelda Ziekenhuis /ID# 279436

    RECRUITING

    Bonheiden, Antwerpen, 2820, Belgium

  • Jessa Ziekenhuis - Campus Virga Jesse /ID# 279454

    RECRUITING

    Hasselt, Limburg, 3500, Belgium

  • UZ Gent /ID# 279433

    RECRUITING

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • Universitair Ziekenhuis Antwerpen /ID# 279434

    RECRUITING

    Edegem, Antwerpen, 2650, Belgium

  • Universitair Ziekenhuis Leuven /ID# 279439

    RECRUITING

    Leuven, Vlaams-Brabant, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.